Aspirin response variability assessed with the PFA-100 device

Thromb Haemost 2008; 99(05): 968-969
DOI: 10.1160/TH08-02-0123

Letters to the Editor

Schattauer GmbH

Jean-Luc Reny

¹Department of Internal Medicine, Béziers Hospital, Béziers, France

²EA 2992, Montpellier 1 University, Nîmes, France

,

Isabelle Quéré

²EA 2992, Montpellier 1 University, Nîmes, France

,

Philippe de Moerloose

³Division of Angiology and Haemostasis, Department of Internal Medicine, Faculty of Medicine and University Hospitals of Geneva, Geneva, Switzerland

,

Pierre Fontana

³Division of Angiology and Haemostasis, Department of Internal Medicine, Faculty of Medicine and University Hospitals of Geneva, Geneva, Switzerland

References
1 Crescente M, Di Castelnuovo A, Iacoviello L. et al. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost 2008; 99: 14-26.
2 Hovens MM, Snoep JD, Eikenboom JC. et al. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007; 153: 175-181.
3 Krasopoulos G, Brister SJ, Beattie WS. et al. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. Br Med J 2008; 26 (336) 195-198.
4 Fontana P, Reny JL. Laboratory-defined aspirin resistance and recurrent cardiovascular events. Arch Intern Med 2008; 168: 549-550.
5 Reny JL, De Moerloose P, Dauzat M. et al. Use of the PFA-100™ closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2008; 6: 444-450.